Mars announced that it has completed its previously announced acquisition of Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE.
Both businesses will join the Mars Science & Diagnostics division, along with the veterinary diagnosis business Antech and cat and dog genetic player Wisdom Panel.
It is expected that the acquisition will help Mars enhance the reach of its veterinary diagnostics business to European-based veterinarians and drive its research and development (R&D) capabilities.
Successful discussions
Mars started “exclusive discussions” with Cerba HealthCare Group, a network of 6 veterinary diagnostics laboratories in France and Switzerland, to acquire its stake in both companies.
Emmanuel Ligner, CEO of Cerba HealthCare, called Mars Science & Diagnostics “the right investor” as it would support the long-term development and growth of the businesses.
The latest articles
Australia: New South Wales to grant more rights to pet-owning tenants
The reform in the Australian state will ban no-ground evictions and limit landlords' ability to refuse tenants with pets.
Pet brands score big with major sports partnerships
From food producers to insurance providers, this trend aims to improve market visibility.
Study shows gaps in American pet owners' preparedness for natural disasters
How are pet owners prioritizing their concerns when preparing emergency kits for their furry companions?
Weekly newsletter to stay up-to-date
Discover what’s happening in the pet industry. Get the must-read stories and insights in your inbox.